Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
Go back to Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint| (NASDAQ: NVCR) | Delayed: 16.74 +0.52 (3.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.22 | 52 Week High | $28.95 | |||
| Open | $16.58 | 52 Week Low | $5.95 | |||
| Day High | $16.81 | P/E | N/A | |||
| Day Low | $16.13 | EPS | $0.00 | |||
| Volume | 260,509 | |||||
| (NASDAQ: ZLAB) | Delayed: 25.64 +0.97 (3.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.67 | 52 Week High | $ | |||
| Open | $25.25 | 52 Week Low | $ | |||
| Day High | $25.77 | P/E | N/A | |||
| Day Low | $25.03 | EPS | $ | |||
| Volume | 153,460 | |||||
